Claims for Patent: 11,957,753

Summary for Patent: 11,957,753

Title:	Pharmaceutical formulations containing corticosteroids for topical administration
Abstract:	Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Inventor(s):	Arturo Angel, Gordon Dow
Assignee:	Bausch Health Ireland Ltd
Application Number:	US15/966,367
Patent Claims:	1. A pharmaceutical composition for topical application to the skin of an individual comprising: a liquid oil component comprising a dicarboxylic acid ester or a monocarboxylic acid ester, and a mineral oil or a light mineral oil; a corticosteroid at a concentration of 0.03% or less, wherein the corticosteroid is selected from the group consisting of halobetasol propionate, clobetasol, betamethasone dipropionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, fluocinonide, and amcinonide, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.±2° C.; and an aqueous component comprising water; wherein the pharmaceutical composition does not include white petrolatum; and wherein the pharmaceutical composition is formulated as a lotion or a cream. 2. The pharmaceutical composition of claim 1, wherein the corticosteroid is halobetasol propionate. 3. The pharmaceutical composition of claim 1, wherein the corticosteroid is clobetasol propionate. 4. The pharmaceutical composition of claim 1, wherein the corticosteroid is betamethasone dipropionate. 5. The pharmaceutical composition of claim 1, wherein the corticosteroid is diflorasone diacetate. 6. The pharmaceutical composition of claim 1, wherein the corticosteroid is desoximetasone. 7. The pharmaceutical composition of claim 1, wherein the concentration of the corticosteroid is about 0.01%. 8. The pharmaceutical composition of claim 1, wherein the liquid oil component comprises a dicarboxylic acid ester, and the dicarboxylic acid ester is diethyl sebacate, diisopropyl adipate, or dibutyl sebacate. 9. The pharmaceutical composition of claim 8, wherein the dicarboxylic acid ester is diethyl sebacate. 10. The pharmaceutical composition of claim 1, wherein the liquid oil component comprises a monocarboxylic acid ester. 11. The pharmaceutical composition of claim 10, wherein the monocarboxylic acid ester is isopropyl myristate. 12. The pharmaceutical composition of claim 1, wherein the liquid oil component comprises light mineral oil. 13. The pharmaceutical composition of claim 1, wherein the concentration of the liquid oil component is sufficient to dissolve the amount of corticosteroid in the composition at a temperature of 22° C.±2° C. 14. The pharmaceutical composition of claim 1, wherein the liquid oil component further comprises an emulsifying agent. 15. The pharmaceutical composition of claim 1, wherein the aqueous component further comprises one or more humectants, preservatives, chelating agents, emulsifying agents, and/or thickening agents. 16. The pharmaceutical composition of claim 1, further comprising a pH adjusting agent. 17. The pharmaceutical composition of claim 1, wherein the composition is formulated as an oil-in-water emulsion, a water-in-oil emulsion, or an oil-in-water-in-oil emulsion. 18. The pharmaceutical composition of claim 1, wherein the composition is formulated as a lotion. 19. A pharmaceutical composition for topical application to the skin of an individual comprising: a liquid oil component comprising a dicarboxylic acid ester or a monocarboxylic acid ester, and a mineral oil or a light mineral oil; a corticosteroid at a concentration of 0.01% or less, wherein the corticosteroid is selected from the group consisting of halobetasol propionate, clobetasol, betamethasone dipropionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, fluocinonide, or amcinonide, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.±2° C.; and an aqueous component comprising water; wherein the pharmaceutical composition does not include white petrolatum; and wherein the pharmaceutical composition is formulated as a lotion or a cream. 20. The pharmaceutical composition of claim 19, wherein the corticosteroid is halobetasol propionate. 21. The pharmaceutical composition of claim 1, wherein the concentration of the corticosteroid is from about 0.01% to about 0.03%. 22. The pharmaceutical composition of claim 2, wherein the concentration of the halobetasol propionate is about 0.01%, and wherein the dicarboxylic acid ester is diethyl sebacate. 23. The pharmaceutical composition of claim 20, wherein the concentration of the halobetasol propionate is about 0.01%, and wherein the pharmaceutical composition is formulated as a lotion.